Tag: Servier

Servier Announced Acquisition of PIXUVRI® from CTI BioPharma

Servier, an independent international pharmaceutical company, announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory a...

BI, Eli Lilly, Sanofi, Servier Develop Drug-Drug Interaction Risk Calculator

Elsevier, an information analytics business, is working together with a set of evaluation partners including Boehringer Ingelheim, Eli Lilly, Pierre Fabre, Sanofi, Servier, and others to develop a new...

EC Approved LONSURF® as Monotherapy for Treatment of Metastatic Gastric Cancer

Servier and its partner Taiho Pharmaceutical Co., Ltd announced that the European Commission (EC) has approved the use of LONSURF® (trifluridine/tipiracil) as monotherapy for the treatment of adult pa...

Servier Announced First Private Placement on the US Market

Servier, an independent international pharmaceutical group, is announcing that it has successfully made an inaugural private placement for 405 million dollars on the US private placement (USPP) market...

Servier Australia and BioCurate Agreed to Share Expertise to Accelerate the Discovery of New Drugs

Servier Australia, the subsidiary of Servier Group, an international pharmaceutical company, and BioCurate, a joint venture company of Monash University and The University of Melbourne with support fr...

Servier Announce First eHealth Partnership Between Two French Companies

WeHealth Digital Medicine, Servier Group’s eHealth division, and Lucine, a pioneering French innovative company specializing in digital therapeutics, have announced their joint development partnership...

Servier Laid Foundation Stone of its Future Research Institute

Servier, an independent international pharmaceutical company, has laid the foundation stone of its future Research Institute in the Paris-Saclay cluster. The new Servier Paris-Saclay Research Institut...

Servier Picked Yposkesi for Lentiviral Vector GMP-manufacturing in CAR-T Cell Development Technology...

Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, announced that they have signed a manufacturing service agreemen...

Servier Launched the Production of a Drug for the Treatment of HIV infection

On April 25, the first production line of an innovative drug for the treatment of HIV infection in Russia was launched at the Servier pharmaceutical plant in Moscow. Alexander Prokhorov, Head of th...

Servier and Oncodesign Team Up for R&D Parkinson’s Drug

Servier, an international pharmaceutical company governed by a non-profit foundation, and biopharmaceutical company, Oncodesign have announced a strategic partnership for the research and development ...

Servier celebrated 15 years of operation in Georgia

French pharmaceutical group 'Servier' celebrated 15 years of operation in Georgia at an event attended by representatives of the Ministry of Health, industry specialists and company partners. The o...

The European Union’s General Court reduces cartel fine on Servier

The European Union’s General Court has reduced an EU fine on the French pharmaceutical company Servier

Servier and the Government of Kazakhstan agreed on cooperation

Servier, a French pharmaceutical company, and National Company KAZAKH INVEST JSC have signed an agreement on cooperation in the area of pharmaceutical manufacturing.

French company will set up a production of innovative medicines in Kazakhstan

At the meeting on global investments held in Astana, the companies of Kazakhstan signed 32 commercial documents for the total amount of $4.7 billion.

Manufacturing of Tivicay® in Moscow will be launched no later than May 2019

GSK and Servier signed an agreement to launch the manufacturing of innovative HIV drug Tivicay® (INN: dolutegravir) in the production facility of Servier Rus pharmaceutical plant in Moscow.

Servier introduced its new Effient drug to the Russian market

Servier announced that sales of Effient®, its innovative last-generation antiplatelet agent, began in Russia in March 2018. The license agreement covering the territory of Russia was signed with Daiichi Sankyo in July 2016.